Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Stomach Neoplasms 4Colonic Neoplasms 2To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Rectal Neoplasms 1Platinum Resistant Ovarian Cancer 1Neoplasm Metastasis 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Advanced Gastric Cancer 1

Interventions

Cyclophosphamide 4trastuzumab deruxtecan 3fludarabine 3Standard of Care 3Injections 3Cisplatin 3Bevacizumab 3toripalimab 2sacituzumab govitecan 2pembrolizumab 2fludarabine phosphate 2Specimen Handling 2Radiosurgery 2Pemetrexed 2Palliative Care 2Gemcitabine 2Fulvestrant 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2zimberelimab 1vedolizumab 1tislelizumab 1sintilimab 1lobaplatin 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1exemestane 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasm Metastasis × HMPL-013 × Clear all
NCT07446465 2026-03-03

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Fudan University

Phase 4 Not yet recruiting
42 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡